← Back to guidelines
Cardiology53 papers

Malignant eccrine spiradenoma

Last edited: 4/22/2026

Overview

Malignant eccrine spiradenoma is a rare, aggressive variant of eccrine spiradenoma, characterized by malignant transformation of sweat gland tumors. It typically presents as a deep-seated, painful mass with potential for local invasion and metastasis 12.

Diagnosis

  • Biopsy revealing malignant transformation of eccrine spiradenoma cells
  • Immunohistochemical staining for markers indicative of malignancy (details not specified in abstracts)
  • Imaging (MRI, CT) to assess local invasion and potential metastasis
  • Histopathological examination confirming atypical cellular features and mitotic activity 12
  • Management

  • Surgical excision with wide margins is essential for local control 12
  • Adjuvant radiotherapy may be considered for residual disease or high-risk features 12
  • Chemotherapy regimens are not well-defined; may include drugs targeting angiogenic pathways given VHL alterations 1
  • Special Populations

  • Limited data; management principles likely similar across age groups but individualized care required 12
  • No specific recommendations for pregnancy or comorbidities noted 12
  • Key Recommendations

  • Confirm diagnosis through histopathological examination with immunohistochemical analysis 12 (Evidence: Moderate)
  • Primary treatment should involve wide surgical excision to achieve local control 12 (Evidence: Moderate)
  • Consider adjuvant radiotherapy for high-risk features or incomplete resection 12 (Evidence: Moderate)
  • References

    1 Shiao YH. The von Hippel-Lindau gene and protein in tumorigenesis and angiogenesis: a potential target for therapeutic designs. Current medicinal chemistry 2003. link 2 Wang R, Bautch VL. The polyomavirus early region gene in transgenic mice causes vascular and bone tumors. Journal of virology 1991. link

    Original source

    1. [1]
    2. [2]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG